Debiopharm and Ipsen announced renewal of their Decapeptyl agreement, which extends and strengthens their strategic partnership through 2034 for the development, manufacturing and distribution of Decapeptyl across Europe and certain Asian and African markets.
UK-based Theramex has agreed to acquire exclusive licensing and supply rights from TherapeuticsMD to commercialise BIJUVA (estradiol and progesterone capsules) and IMVEXXY (estradiol vaginal inserts) outside of the US.
Neuraxpharm Group, a provider of treatments for central nervous system (CNS) disorders, is set to introduce its first probiotic in the European market.
Italy-based Chiesi Farmaceutici (Chiesi Group) has agreed to buy the licensing rights of Raxone (idebenone), an approved drug for Leber's hereditary optic neuropathy (LHON) in Europe, from Swiss pharma company Santhera Pharmaceuticals in a deal worth up to CHF105m (£82.5m).
Novartis has agreed to acquire dry eye drug Xiidra (lifitegrast ophthalmic solution) 5% from Takeda for $3.4bn.
Ligand Pharmaceuticals and Royalty Pharma announce the sale of Ligand’s Promacta-related intellectual property rights licensed to Novartis, including the royalty stream on worldwide net sales of Promacta to Royalty Pharma for $827m in cash.
Bausch Health announced that the company was selected as the successful bidder to acquire certain assets of Synergy Pharmaceuticals for a cash purchase price of approximately $195m and the assumption of certain assumed liabilities, pursuant to the terms of the stalking horse asset purchase agreement previously entered into with the company.
UK-based Clinigen Group has agreed to acquire the US rights to Proleukin (aldesleukin, human recombinant interleukin-2) from Novartis in an all-cash deal worth up to $210m.
ValGenesis has announced that one of the world's largest, top rated life science companies has chosen to implement its 100% paperless Validation Lifecycle Management System (VLMS) across all its global sites to manage the corporate validation lifecycle process.
Swedish Orphan Biovitrum AB (Sobi) has completed the acquisition of US rights of Synagis (palivizumab) from AstraZeneca in a deal valued at around $1.6bn.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.